Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;17(1):e13683.
doi: 10.1111/cts.13683. Epub 2023 Nov 22.

Expanding regulatory science: Regulatory complementarity and reliance

Affiliations

Expanding regulatory science: Regulatory complementarity and reliance

Jackson K Mukonzo et al. Clin Transl Sci. 2024 Jan.

Abstract

Drug regulatory institutions, infrastructures, and systems are becoming increasingly interconnected across national boundaries and increasingly global in outlook. This process is reflected in the broadening and deepening application of the principles and practice of Regulatory Reliance, and parallel initiatives to strengthen the capacities of regulatory institutions in low- and middle-income countries (LMICs). Although these developments are important and constructive, they have tended to be framed in terms of the transfer of systems, knowledge, and skills from relatively "mature" regulatory agencies in high-income countries (HICs) to less-well-resourced regulatory agencies in LMICs. This framing recognizes and foregrounds the considerable practical challenges that many LMIC regulatory agencies face, but in doing so, also backgrounds and underestimates the significance of the different contextual insights that LMIC health researchers and regulators can bring to the regulatory deliberations of their HIC counterparts. This position paper argues that the systematic pursuit, identification, and sharing of these different contextual insights-a dimension of regulatory science that we term "Regulatory Complementarity"-can augment the current practice and goals of Regulatory Reliance, and further invigorate the emerging global regulatory ecosystem.

PubMed Disclaimer

Conflict of interest statement

The authors declared no competing interests for this work.

References

    1. Lumpkin MM, Hamburg MA, Schultz WB, Sharfstein JM. Transparency practices at the FDA: A barrier to global health. Science. 2022;377(6606):572‐574. doi:10.1126/science.abq4981 - DOI - PubMed
    1. Vaz A, Santos MR, Gwaza L, et al. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action? Exp Rev Clin Pharmacol. 2022;15(1):11‐17. - PubMed
    1. Project ORBIS . https://www.fda.gov/about‐fda/oncology‐center‐excellence/project‐orbis Accessed September 13, 2023
    1. European Medicines Agency . Questions and Answers on the Pilot Project ‘OPEN.’ 2021. https://www.ema.europa.eu/en/documents/other/questions‐answers‐pilot‐pro... Accessed 01/06/2023.
    1. Public Health Threats . https://www.ema.europa.eu/en/human‐regulatory/overview/public‐health‐thr... Accessed September 13, 2023.